Category Archives: IMS Monthly data Vytorin Zetia Hassan Updated Investor

Didn’t Schering CEO Hassan Promise Monthly Updates on Vytorin/Zetia Scrips?

[UPDATED — 05.28.08 PM The numbers are up — and they are. . . UGLY. Take a look — off 22.25 percent.

05.25.08 — 2:00 PM: It occurs to me that Friday’s nearly 2.6 percent, end-of-day drop in Schering-Plough common stock prices per share, on the NYSE may be, in part, due to some people (IMS subscribers?) having already deduced that the April monthly IMS data is rather ominous.]

Actually, he did make that promise in January 2008. On February 22, March 17, and April 21, 2008 — he posted revised-Investor FAQs disclosures on the Schering-Plough website, and filed them with the SEC as Forms 8-K. Each of those documents contained monthly Vytorin/Zetia prescription data, from IMS.

By the time Tuesday rolls around, the May version (containing April numbers) will be about a week overdue.

This came up over on Pharmalot, in the comments, as we talked about waiting to see whether Sen. John McCain’s switch to a generic version of Zocor (away from Vytorin) was emblematic of newly emerging nation-wide trends, or simply an exception to the new trends. At that moment I thought we’d need to wait for the next quarterly report from Schering and Merck. I had forgotten, for the moment, about Mr. Hassan’s commitment to furnish monthly data to the investing public. But no longer.

[Note to self — call Kennilworth for a comment, if an updated Investors’ FAQ document is not posted by this coming Friday.]

Didn’t Schering CEO Hassan Promise Monthly Updates on Vytorin/Zetia Scrips?

[UPDATED — 05.28.08 PM The numbers are up — and they are. . . UGLY. Take a look — off 22.25 percent.

05.25.08 — 2:00 PM: It occurs to me that Friday’s nearly 2.6 percent, end-of-day drop in Schering-Plough common stock prices per share, on the NYSE may be, in part, due to some people (IMS subscribers?) having already deduced that the April monthly IMS data is rather ominous.]

Actually, he did make that promise in January 2008. On February 22, March 17, and April 21, 2008 — he posted revised-Investor FAQs disclosures on the Schering-Plough website, and filed them with the SEC as Forms 8-K. Each of those documents contained monthly Vytorin/Zetia prescription data, from IMS.

By the time Tuesday rolls around, the May version (containing April numbers) will be about a week overdue.

This came up over on Pharmalot, in the comments, as we talked about waiting to see whether Sen. John McCain’s switch to a generic version of Zocor (away from Vytorin) was emblematic of newly emerging nation-wide trends, or simply an exception to the new trends. At that moment I thought we’d need to wait for the next quarterly report from Schering and Merck. I had forgotten, for the moment, about Mr. Hassan’s commitment to furnish monthly data to the investing public. But no longer.

[Note to self — call Kennilworth for a comment, if an updated Investors’ FAQ document is not posted by this coming Friday.]

Didn’t Schering CEO Hassan Promise Monthly Updates on Vytorin/Zetia Scrips?

[UPDATED — 05.28.08 PM The numbers are up — and they are. . . UGLY. Take a look — off 22.25 percent.

05.25.08 — 2:00 PM: It occurs to me that Friday’s nearly 2.6 percent, end-of-day drop in Schering-Plough common stock prices per share, on the NYSE may be, in part, due to some people (IMS subscribers?) having already deduced that the April monthly IMS data is rather ominous.]

Actually, he did make that promise in January 2008. On February 22, March 17, and April 21, 2008 — he posted revised-Investor FAQs disclosures on the Schering-Plough website, and filed them with the SEC as Forms 8-K. Each of those documents contained monthly Vytorin/Zetia prescription data, from IMS.

By the time Tuesday rolls around, the May version (containing April numbers) will be about a week overdue.

This came up over on Pharmalot, in the comments, as we talked about waiting to see whether Sen. John McCain’s switch to a generic version of Zocor (away from Vytorin) was emblematic of newly emerging nation-wide trends, or simply an exception to the new trends. At that moment I thought we’d need to wait for the next quarterly report from Schering and Merck. I had forgotten, for the moment, about Mr. Hassan’s commitment to furnish monthly data to the investing public. But no longer.

[Note to self — call Kennilworth for a comment, if an updated Investors’ FAQ document is not posted by this coming Friday.]

Didn’t Schering CEO Hassan Promise Monthly Updates on Vytorin/Zetia Scrips?

[UPDATED — 05.28.08 PM The numbers are up — and they are. . . UGLY. Take a look — off 22.25 percent.

05.25.08 — 2:00 PM: It occurs to me that Friday’s nearly 2.6 percent, end-of-day drop in Schering-Plough common stock prices per share, on the NYSE may be, in part, due to some people (IMS subscribers?) having already deduced that the April monthly IMS data is rather ominous.]

Actually, he did make that promise in January 2008. On February 22, March 17, and April 21, 2008 — he posted revised-Investor FAQs disclosures on the Schering-Plough website, and filed them with the SEC as Forms 8-K. Each of those documents contained monthly Vytorin/Zetia prescription data, from IMS.

By the time Tuesday rolls around, the May version (containing April numbers) will be about a week overdue.

This came up over on Pharmalot, in the comments, as we talked about waiting to see whether Sen. John McCain’s switch to a generic version of Zocor (away from Vytorin) was emblematic of newly emerging nation-wide trends, or simply an exception to the new trends. At that moment I thought we’d need to wait for the next quarterly report from Schering and Merck. I had forgotten, for the moment, about Mr. Hassan’s commitment to furnish monthly data to the investing public. But no longer.

[Note to self — call Kennilworth for a comment, if an updated Investors’ FAQ document is not posted by this coming Friday.]

Didn’t Schering CEO Hassan Promise Monthly Updates on Vytorin/Zetia Scrips?

[UPDATED — 05.28.08 PM The numbers are up — and they are. . . UGLY. Take a look — off 22.25 percent.

05.25.08 — 2:00 PM: It occurs to me that Friday’s nearly 2.6 percent, end-of-day drop in Schering-Plough common stock prices per share, on the NYSE may be, in part, due to some people (IMS subscribers?) having already deduced that the April monthly IMS data is rather ominous.]

Actually, he did make that promise in January 2008. On February 22, March 17, and April 21, 2008 — he posted revised-Investor FAQs disclosures on the Schering-Plough website, and filed them with the SEC as Forms 8-K. Each of those documents contained monthly Vytorin/Zetia prescription data, from IMS.

By the time Tuesday rolls around, the May version (containing April numbers) will be about a week overdue.

This came up over on Pharmalot, in the comments, as we talked about waiting to see whether Sen. John McCain’s switch to a generic version of Zocor (away from Vytorin) was emblematic of newly emerging nation-wide trends, or simply an exception to the new trends. At that moment I thought we’d need to wait for the next quarterly report from Schering and Merck. I had forgotten, for the moment, about Mr. Hassan’s commitment to furnish monthly data to the investing public. But no longer.

[Note to self — call Kennilworth for a comment, if an updated Investors’ FAQ document is not posted by this coming Friday.]

Didn’t Schering CEO Hassan Promise Monthly Updates on Vytorin/Zetia Scrips?

[UPDATED — 05.28.08 PM The numbers are up — and they are. . . UGLY. Take a look — off 22.25 percent.

05.25.08 — 2:00 PM: It occurs to me that Friday’s nearly 2.6 percent, end-of-day drop in Schering-Plough common stock prices per share, on the NYSE may be, in part, due to some people (IMS subscribers?) having already deduced that the April monthly IMS data is rather ominous.]

Actually, he did make that promise in January 2008. On February 22, March 17, and April 21, 2008 — he posted revised-Investor FAQs disclosures on the Schering-Plough website, and filed them with the SEC as Forms 8-K. Each of those documents contained monthly Vytorin/Zetia prescription data, from IMS.

By the time Tuesday rolls around, the May version (containing April numbers) will be about a week overdue.

This came up over on Pharmalot, in the comments, as we talked about waiting to see whether Sen. John McCain’s switch to a generic version of Zocor (away from Vytorin) was emblematic of newly emerging nation-wide trends, or simply an exception to the new trends. At that moment I thought we’d need to wait for the next quarterly report from Schering and Merck. I had forgotten, for the moment, about Mr. Hassan’s commitment to furnish monthly data to the investing public. But no longer.

[Note to self — call Kennilworth for a comment, if an updated Investors’ FAQ document is not posted by this coming Friday.]

Didn’t Schering CEO Hassan Promise Monthly Updates on Vytorin/Zetia Scrips?

[UPDATED — 05.28.08 PM The numbers are up — and they are. . . UGLY. Take a look — off 22.25 percent.

05.25.08 — 2:00 PM: It occurs to me that Friday’s nearly 2.6 percent, end-of-day drop in Schering-Plough common stock prices per share, on the NYSE may be, in part, due to some people (IMS subscribers?) having already deduced that the April monthly IMS data is rather ominous.]

Actually, he did make that promise in January 2008. On February 22, March 17, and April 21, 2008 — he posted revised-Investor FAQs disclosures on the Schering-Plough website, and filed them with the SEC as Forms 8-K. Each of those documents contained monthly Vytorin/Zetia prescription data, from IMS.

By the time Tuesday rolls around, the May version (containing April numbers) will be about a week overdue.

This came up over on Pharmalot, in the comments, as we talked about waiting to see whether Sen. John McCain’s switch to a generic version of Zocor (away from Vytorin) was emblematic of newly emerging nation-wide trends, or simply an exception to the new trends. At that moment I thought we’d need to wait for the next quarterly report from Schering and Merck. I had forgotten, for the moment, about Mr. Hassan’s commitment to furnish monthly data to the investing public. But no longer.

[Note to self — call Kennilworth for a comment, if an updated Investors’ FAQ document is not posted by this coming Friday.]